Sichenzia Ross Ference LLP Represents AIT Therapeutics in $8 Million Private Placement
Press Release – New York, NY – June 4, 2019 – Sichenzia Ross Ference LLP announced today that it has represented AIT Therapeutics, Inc. (NASDAQ:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, in a $8 million private placement of its common stock.
The Company issued approximately 1.6 million shares of common stock at a purchase price of $5.00 per share. The private placement was made directly by the Company without an underwriter or placement agent.
The Sichenzia Ross Ference team was led by Partners Gregory Sichenzia and Avital Perlman.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Attorneys Selected for Inclusion on 2019 Super Lawyers Lists - October 16, 2019
- Sichenzia Ross Ference LLP to Join Client Relmada Therapeutics, Inc. at Nasdaq Opening Bell Ringing - October 15, 2019
- Sichenzia Ross Ference LLP Congratulates Relmada Therapeutics, Inc., on NASDAQ Uplisting - October 10, 2019